Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke

NCT07519889 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

4500

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Ischemic Stroke
rhTNK-tPA

Interventions

DRUG: rhTNK-tPA
DRUG: rt-PA

Sponsor

CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.